Chronic Obstructive Pulmonary Disease Clinical Trial
Official title:
Observational, Multi-centre, Retrospective Cohort Study to Evaluate Prevalence, Incidence, Severity, Co-morbidities and Burden of Disease in Patients With a Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) by Close Scrutiny of the Patient Journey
The investigators will describe the characteristics, prevalence, incidence, severity co-morbidity and management of patients with chronic obstructive pulmonary disease (COPD) in the UK. 100 practices will be sampled amounting to a total study population of about 10 000 patients. Information will be collected electronically and, where necessary, by a hand search of patient records.
Research questions:
1. What is the recorded prevalence of COPD in the UK? [numerator: the prevalence of COPD
defined as ANY current READ code for COPD or inclusion in a COPD register denominator:
the whole population]
- What proportion of this population has documented spirometry to confirm the
diagnosis?
- What proportion has documented spirometry in the last year?
- What proportion has ever had a documented history of asthma?
- What proportion currently has a documented history of asthma?
- What proportion currently smokes?
- What proportion of smokers has a record of receiving smoking cessation advice?
- What proportion of smokers has had a prescription for smoking cessation therapy?
- What proportion of people with COPD has a READ code for exception reporting?
- What are their demographic features? (height weight, BMI, age, smoking status,
forced expiratory flow in 1st second (FEV1_, DOSE)
- What proportion of people with COPD has a READ code for exception reporting from
spirometry?
- What are their demographic features? (height, weight, body mass index (BMI), age,
smoking status, FEV1, DOSE)
Sub analysis: descriptions and comparison of prevalence by • Age
• geographical location of participating practices
• primary care training practice
• number of performing general practitioners (GPs) in practice (<3 v >/= 3)
2. What is the incidence of COPD in the UK
• number of people with a new diagnosis of COPD in the last year as a proportion of the
whole population
3. What is the distribution of severities of COPD?
• Description of severity of airflow obstruction by FEV1 measurement:
Mild (FEV1 ≥ 80% predicted):
Moderate (FEV1 50% to 79% predicted) Severe (FEV1 30% to 49% predicted) Very severe
(FEV1 ≤ 30% predicted)
• And by DOSE
Compare the severity of disease (exacerbation rate) according to DOSE "high risk" and
"low risk" and compare this to the stratification of severity in the study population
by degree of airflow limitation.
• And by COPD Assessment Test (CAT)
Explore the use of CAT in clinical practice and the availability and spread of data
4. What is the exacerbation rate?
- In the last year in people with a diagnosis of COPD > 1 year
- In the last three years in people with a diagnosis of COPD > 3years (as a
proportion of the population with COPD).
- What is the seasonal variation of COPD exacerbations: what proportion of
exacerbations occurs in each month of the year?
- Do recurrent primary care managed exacerbations predict hospital admissions? What
is the prior exacerbation rate in patients admitted to hospital? Population of
interest: those with hospital admissions for COPD: what is the exacerbation rate
(and time frame of exacerbations) prior to a hospital admission?
4a. What proportion of the COPD population had at least one exacerbation?
Hospital attendance: Any documented visit to any secondary care (not primary care out
of hours) site with no overnight stay
Hospital admission: Any documented visit to any secondary care site with an overnight
stay with a principal diagnosis of COPD or chest infection or pneumonia or exacerbation
of asthma ICU admission: Any documented admission to any high dependency unit (note, AN
EXPLORATORY EXERCISE. Validity of this data in primary care record is questionable)
Death: Any death with COPD documented as the primary cause or within 14 days of the
onset of an exacerbation (EXPLORATORY)
- Does DOSE predict undesirable outcomes (death, hospital admission, exacerbation
rate)?
- Does FEV1 predict undesirable outcomes (death, hospital admission, exacerbation
rate)?
- Does medical research council dyspnoea (MRC) score (or other component of DOSE)
predict undesirable outcomes?
- Possible exploratory analysis: does ADO index (Age, Dyspnoea (MRC score)
Obstruction (FEV1 % pred)) predict undesirable outcomes?
- Does number of patients in a practice receiving a Tiotropium prescription predict
hospital admission at a practice level?
5. Therapy:
- What proportion of patients (without a diagnosis of asthma) receives inhaled
glucocorticosteroids at unlicensed doses (any steroid (fluticasone, budesonide,
beclometasone, ciclesonide) or combination Seretide, Symbicort, Fostair) EXCEPT
Seretide Accuhaler 50/500 or Symbicort?
- What proportion of patients with FEV1> 50 and no diagnosis of asthma receive any
steroid preparation? (Note: Seretide Accuhaler 50/500 is licensed for use in
patients with COPD and (pre-bronchodilator) FEV1 < 60% predicted and is therefore
not subject to off label use in this instance). The approach outlined here is a
consensus for the purposes of identifying a pragmatic approach to data collection.
- What proportion of patients with FEV<50 do not receive any inhaled steroid?
- What proportion of patients with 1 or more exacerbation in the last year does not
receive any inhaled steroid?
- What proportion of patients with FEV1 <50 do not receive Seretide 50/500 or
Symbicort?
- What proportion of patients are on "triple therapy" i.e. Seretide or Symbicort
PLUS Tiotropium, classified by severity (FEV1)
- What is the refill rate for prescriptions by class (all above and SABA) in the
previous year?
- What proportion of patients have an MRC dyspnoea score >/= 3?
- What proportion of these patients has been referred for pulmonary rehabilitation?
- What proportion has received pulmonary rehabilitation?
- What proportion has documented evidence of receiving a self management plan?
6. Co-morbidities:
What proportion of patients with COPD have any READ code ever for the following
co-morbidities:
- Cardiovascular disease
- Cerebrovascular disease
- Diabetes Mellitus
- Cancer
- Lung cancer
- Depression
- Osteoporosis What proportion of patients with at least one comorbidity has
attended a specialist chest service / clinic in the last year? What is the
exacerbation rate in this group v patients without comorbidity? What is the
hospital admission rate in this group v the rest? What proportion of the
population has a record of NEVER smoking? What are the features of this group
(age, sex, geography, exacerbation rate, medication, comorbidities
7. Newly diagnosed patients
- What are the characteristics (demographics: height weight, BMI, age, smoking
status, FEV1, DOSE) of newly diagnosed patients (first READ code for COPD within
the last year)?
- What proportion of these patients received a prescription for Tiotropium within 1
month of diagnosis?
- What proportion of these patients received a prescription for an inhaled
corticosteroid / longa acting beta-agonist fixed dose (ICS / LABA) combination
within 1 month of diagnosis?
- In patients FEV1 <50% predicted, what proportion receive a) Tiotropium and b) an
ICS / LABA combination first
- What proportion of these patients with FEV1>50 received a prescription for ICS /
LABA combination within 1 month of diagnosis?
8. General Practice Research database (GPRD)
- What proportion of our sample currently contributes to the GPRD database?
- Are their differences in the features of the two groups: Age geographical location
of participating practices, primary care training practice, number of performing
GPs in practice (<3 v >/= 3), disease severity (DOSE, FEV1) exacerbation rate
9. What changes have there been at practice level to the above parameters in the last
year?
;
Observational Model: Cohort, Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|